Postoperative Hematoma After Facelift in a Patient on Direct Oral Anticoagulant
A 62-year-old woman undergoes a rhytidectomy and platysmaplasty. Her medical history includes atrial fibrillation, for which she takes apixaban 5 mg twice daily. The surgeon instructed her to hold apixaban for 48 hours before surgery, and the procedure was performed under general anesthesia. The surgery was uneventful, and she was discharged the same day with a drain in place. On postoperative day 1, she calls the office reporting a rapidly expanding swelling on the right side of her neck, difficulty swallowing, and a sensation of pressure in her throat. She is 45 minutes away from the office. Her oxygen saturation is 94% on room air, and she appears anxious. The drain output has been minimal.
1. What is the most likely diagnosis, and what immediate steps should be taken? Include the reasoning for your answer.
Read the worked answer
The most likely diagnosis is an expanding neck hematoma causing airway compromise. The patient is on apixaban, which was held for only 48 hours; the half-life of apixaban is about 12 hours, so 48 hours corresponds to about 4 half-lives, meaning approximately 6% of the drug remains, but the effect can be variable, and the patient may still be anticoagulated. The rapid swelling, difficulty swallowing, and throat pressure are warning signs of a hematoma that can obstruct the airway. Immediate steps: instruct the patient to call 911 or go to the nearest emergency department immediately; do not wait for an office visit. In the emergency department, the airway should be assessed; if there is stridor or severe compromise, emergent intubation or surgical airway may be needed. The hematoma should be evacuated, likely in the operating room, and the drain checked. Reversal of apixaban with andexanet alfa or prothrombin complex concentrate may be considered in consultation with hematology, but the priority is airway management and hematoma evacuation. The patient should be monitored closely.
2. How should the surgeon address the timing of apixaban discontinuation for future procedures, and what factors influence this decision?
Read the worked answer
For future procedures, the surgeon should coordinate with the patient's cardiologist or primary care physician to determine the optimal perioperative management of apixaban. The decision depends on the patient's thrombotic risk (CHA2DS2-VASc score) and bleeding risk of the surgery. For a procedure with high bleeding risk like facelift, apixaban should typically be held for at least 2-3 days (4-5 half-lives) before surgery, and possibly longer in patients with renal impairment. Bridging with heparin is generally not recommended for direct oral anticoagulants due to their predictable pharmacokinetics, but may be considered in high thrombotic risk patients. The surgeon should also consider using local hemostatic agents, meticulous hemostasis, and possibly delaying surgery until the patient can safely discontinue the anticoagulant. Shared decision-making with the patient and the prescribing physician is essential.